{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:42:18Z","timestamp":1791477738419,"version":"4.3.4"},"update-to":[{"DOI":"10.1002\/14651858.cd006981.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000}}],"reference-count":89,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006981.pub3","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T10:29:12Z","timestamp":1653042552000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Treatment for sialorrhea (excessive saliva) in people with motor neuron disease\/amyotrophic lateral sclerosis"],"prefix":"10.1002","volume":"2022","author":[{"given":"Eleanor","family":"James","sequence":"additional","affiliation":[{"name":"Alder Hey Children's NHS Foundation Trust; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Ellis","sequence":"additional","affiliation":[{"name":"Motor Nerve Clinic; Academic Neurosciences Centre, King's College Hospital; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Brassington","sequence":"additional","affiliation":[{"name":"Cochrane Neuromuscular, Queen Square Centre for Neuromuscular Diseases; National Hospital for Neurology and Neurosurgery; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivakumar","family":"Sathasivam","sequence":"additional","affiliation":[{"name":"The Walton Centre NHS Foundation Trust; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn A","family":"Young","sequence":"additional","affiliation":[{"name":"The Walton Centre NHS Foundation Trust; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,5,20]]},"reference":[{"key":"10.1002\/14651858.CD006981.pub3-BIB0001|cit1","unstructured":"Gronseth G Cochrane review on treatment for sialorrhoea in ALS\/MND [personal communication] Email to: C Young"},{"issue":"2","key":"10.1002\/14651858.CD006981.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1002\/mus.21213","article-title":"Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients","volume":"39","author":"Jackson","year":"2009","journal-title":"Muscle & Nerve"},{"issue":"1","key":"10.1002\/14651858.CD006981.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"365401","DOI":"10.1080\/2331205X.2017.1365401","article-title":"Efficacy of transdermal scopolamine for sialorrhea in patients with amyotrophic lateral sclerosis","volume":"4","author":"Odachi","year":"2017","journal-title":"Cogent Medicine"},{"key":"10.1002\/14651858.CD006981.pub3-BIB0004|cit4","unstructured":"Assessment of the efficacy and the influence on swallowing function of transdermal scopolamine for ALS patients' drooling upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000013085"},{"key":"10.1002\/14651858.CD006981.pub3-BIB0005|cit5","unstructured":"Clinical trial Nuedexta in subjects with ALS clinicaltrials.gov\/ct2\/show\/NCT01806857"},{"issue":"3","key":"10.1002\/14651858.CD006981.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s13311-016-0508-5","article-title":"Enhanced bulbar function in amyotrophic lateral sclerosis: the Nuedexta treatment trial","volume":"14","author":"Smith","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"3","key":"10.1002\/14651858.CD006981.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/ane.12559","article-title":"Botulinum toxin-A injections vs radiotherapy for drooling in ALS","volume":"134","author":"Weikamp","year":"2016","journal-title":"Acta Neurologica Scandanavica"},{"issue":"2","key":"10.1002\/14651858.CD006981.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/mds.23473","article-title":"Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease","volume":"26","author":"Guidubaldi","year":"2011","journal-title":"Movement Disorders"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006981.pub3-BIB0009|cit9","first-page":"S28","article-title":"Onset of action for rimabotulinumtoxinB in the treatment of adult sialorrhea","volume":"34","author":"Bahroo","year":"2019","journal-title":"Movement Disorder"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006981.pub3-BIB0010|cit10","first-page":"S49","article-title":"Duration of rimabotulinumtoxinB action in the treatment of adult sialorrhea","volume":"34","author":"Isaacson","year":"2019","journal-title":"Movement Disorder"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD006981.pub3-BIB0011|cit11","first-page":"S48","article-title":"RimbotulinumtoxinB in the treatment of adult sialorrhea","volume":"34","author":"Isaacson","year":"2019","journal-title":"Movement Disorder"},{"key":"10.1002\/14651858.CD006981.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/j.toxicon.2016.11.115","article-title":"Mysticol: a controlled study of myobloc in the treatment of sialorrhea in Parkinson's disease and other neurological conditions","volume":"123","author":"Isaacson","year":"2016","journal-title":"Toxicon"},{"issue":"4","key":"10.1002\/14651858.CD006981.pub3-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1001\/jamaneurol.2019.4565","article-title":"Safety and efficacy of RimabotulinumtoxinB for treatment of sialorrhea in adults: a randomized clinical trial","volume":"77","author":"Isaacson","year":"2020","journal-title":"JAMA Neurology"},{"issue":"4","key":"10.1002\/14651858.CD006981.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamaneurol.2019.4565","article-title":"Safety and efficacy of rimabotulinumtoxinB for treatment of sialorrhea in adults: a randomized clinical trial","volume":"77","author":"Isaacson","year":"2020","journal-title":"JAMA Neurology"},{"key":"10.1002\/14651858.CD006981.pub3-BIB0015|cit15","unstructured":"Efficacy and safety study of MYOBLOC\u00ae followed by open-label multiple-treatment with MYOBLOC\u00ae in the treatment of troublesome sialorrhea in adult subjects (MYSTICOL) clinicaltrials.gov\/ct2\/show\/NCT01994109"},{"issue":"15 Suppl 1","key":"10.1002\/14651858.CD006981.pub3-BIB0016|cit16","first-page":"P4.8","article-title":"RimabotulinumtoxinB (MYOBLOC) in the treatment of adult sialorrhea","volume":"92","author":"Ondo","year":"2019","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD006981.pub3-BIB0017|cit17","first-page":"19","article-title":"Pharmacological therapy of sialorrhea in patients with motor neuron disease","volume":"105","author":"Levitskii","year":"2005","journal-title":"Zhurnal Nevropatologii i Psikhiatrii Imeni S. S. Korsakova"},{"issue":"9","key":"10.1002\/14651858.CD006981.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1212\/WNL.61.9.1279","article-title":"A randomized trial of botulinum toxin A for treatment of drooling","volume":"61","author":"Lipp","year":"2003","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006981.pub3-BIB0019|cit19","unstructured":"Toxin treatment for amyotrophic lateral sclerosis (ALS) related sialorrhea (ALS-TOX) clinicaltrials.gov\/ct2\/show\/NCT01551940"},{"issue":"1-2","key":"10.1002\/14651858.CD006981.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000108917","article-title":"Amyotrophic lateral sclerosis in South-East England: a population based study. The South-East England register for amyotrophic lateral sclerosis (SEALS Registry)","volume":"29","author":"Abhinav","year":"2007","journal-title":"Neuroepidemiology"},{"issue":"2","key":"10.1002\/14651858.CD006981.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1002\/mus.23692","article-title":"Volume matters: the influence of different botulinum toxin-A dilutions for sialorrhea in amyotrophic lateral sclerosis","volume":"47","author":"Anagnostou","year":"2013","journal-title":"Muscle & Nerve"},{"issue":"1-2","key":"10.1002\/14651858.CD006981.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0022-510X(01)00631-1","article-title":"External radiation of the parotid glands significantly reduces drooling in patients with motor neurone disease with bulbar paresis","volume":"191","author":"Andersen","year":"2001","journal-title":"Journal of the Neurological Sciences"},{"issue":"5","key":"10.1002\/14651858.CD006981.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1136\/jnnp.67.5.697","article-title":"Botulinum toxin is a useful treatment in excessive drooling in saliva","volume":"67","author":"Bhatia","year":"1999","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006981.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1007\/PL00007719","article-title":"Palliative care in amyotrophic lateral sclerosis","volume":"244","author":"Borasio","year":"1997","journal-title":"Journal of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD006981.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.canrad.2013.01.010","article-title":"Salivary glands radiotherapy to reduce sialorrhea in amyotrophic lateral sclerosis: dose and energy","volume":"17","author":"Bourry","year":"2013","journal-title":"Cancer Radiotherapie"},{"issue":"3","key":"10.1002\/14651858.CD006981.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1212\/WNL.57.3.500","article-title":"Current management of ALS: comparison of the ALS CARE Database and the AAN Practice Parameter","volume":"57","author":"Bradley","year":"2001","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD006981.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/146608200300079536","article-title":"El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis","volume":"1","author":"Brooks","year":"2000","journal-title":"Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders"},{"issue":"1-2","key":"10.1002\/14651858.CD006981.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1113\/jphysiol.1949.sp004364","article-title":"The action of botulinum toxin on the neuro-muscular junction","volume":"109","author":"Burgen","year":"1949","journal-title":"Journal of Physiology"},{"issue":"4","key":"10.1002\/14651858.CD006981.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0306-9877(97)90103-1","article-title":"Sialorrhoea in amyotrophic lateral sclerosis: a hypothesis of a new treatment - botulinum toxin A injections of the parotid glands","volume":"48","author":"Bushara","year":"1997","journal-title":"Medical Hypotheses"},{"issue":"5","key":"10.1002\/14651858.CD006981.pub3-BIB0030|cit30","first-page":"280","article-title":"Treatment of sialorrhoea in neurological diseases with trans-dermic injections of botulinum toxin type A in the parotid glands","volume":"18","author":"Carod Artal","year":"2003","journal-title":"Neurologia"},{"issue":"1-2","key":"10.1002\/14651858.CD006981.pub3-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/s0022-510x(99)00210-5","article-title":"The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III)","volume":"169","author":"Cedarbaum","year":"1999","journal-title":"Journal of the Neurological Sciences"},{"issue":"5","key":"10.1002\/14651858.CD006981.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.parkreldis.2006.05.005","article-title":"Botulinum toxin B ultrasound-guided injections for sialorrhea in amyotrophic lateral sclerosis and Parkinson's disease","volume":"13","author":"Contarino","year":"2007","journal-title":"Parkinsonism & Related Disorders"},{"issue":"4","key":"10.1002\/14651858.CD006981.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00415-008-0738-5","article-title":"Botulinum toxin type-B improves sialorrhea and quality of life in bulbar onset amyotrophic lateral sclerosis","volume":"255","author":"Costa","year":"2008","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD006981.pub3-BIB0034|cit34","unstructured":"Deeks JJ Higgins JPT Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3\u00a0(updated February\u00a02022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"7","key":"10.1002\/14651858.CD006981.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S1474-4422(17)30115-1","article-title":"Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial","volume":"16","author":"Edaravone (MCI-186) ALS 19 Study Group","year":"2017","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD006981.pub3-BIB0036|cit36","first-page":"3203","article-title":"GEMALS: a promising therapy for amyotrophic lateral sclerosis","volume":"15","author":"Geffard","year":"2018","journal-title":"Experimental and Therapeutic Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006981.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/jnnp.69.1.121","article-title":"Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis","volume":"69","author":"Giess","year":"2000","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD006981.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"359-63","DOI":"10.3109\/17482960903264998","article-title":"Botulinum toxin type A for the treatment of sialorrhoea in amyotrophic lateral sclerosis: a clinical and neurophysiological study","volume":"11","author":"Gilio","year":"2010","journal-title":"Amyotrophic Lateral Sclerosis"},{"key":"10.1002\/14651858.CD006981.pub3-BIB0039|cit39","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT"},{"key":"10.1002\/14651858.CD006981.pub3-BIB0040|cit40","unstructured":"Gronseth G SPIT clarifications [personal communication] Email to: CA Young"},{"issue":"4","key":"10.1002\/14651858.CD006981.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1089\/jpm.2010.0308","article-title":"Comparison of radiotherapy types in the treatment of sialorrhea in amyotrophic lateral sclerosis","volume":"14","author":"Guy","year":"2011","journal-title":"Journal of Palliative Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006981.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"242","DOI":"10.2310\/7070.2001.19779","article-title":"Use of radiotherapy for control of sialorrhea in patients with amyotrophic lateral sclerosis","volume":"30","author":"Harriman","year":"2001","journal-title":"Journal of Otolaryngology"},{"key":"10.1002\/14651858.CD006981.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.sjpain.2016.06.012","article-title":"How to analyze the Visual Analogue Scale: myths, truths and clinical relevance","volume":"13","author":"Heller","year":"2016","journal-title":"Scandinavian Journal of Pain"},{"issue":"7048","key":"10.1002\/14651858.CD006981.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/bmj.313.7048.29","article-title":"A new short form individual quality of life measure (SEIQoL-DW): application in a cohort of individuals with HIV\/AIDS","volume":"313","author":"Hickey","year":"1996","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD006981.pub3-BIB0045|cit45","unstructured":"Higgins JPT Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from training.cochrane.org\/handbook\/archive\/v5.1"},{"key":"10.1002\/14651858.CD006981.pub3-BIB0046|cit46","unstructured":"Higgins JPT Lasserson T Chandler J Tovey D Thomas J Flemyng E Methodological expectations of Cochrane intervention reviews community.cochrane.org\/sites\/default\/files\/uploads\/MECIR%20PRINTED%20BOOKLET%20FINAL%20v1.01.pdf"},{"key":"10.1002\/14651858.CD006981.pub3-BIB0047|cit47","unstructured":"Higgins JPT Eldridge S Chapter 23: Including variants on randomized trials. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3\u00a0(updated February\u00a02022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"1","key":"10.1002\/14651858.CD006981.pub3-BIB0048|cit48","first-page":"41","article-title":"Otolaryngologic manifestations of amyotrophic lateral sclerosis","volume":"17","author":"Janzen","year":"1988","journal-title":"Journal of Otolaryngology"},{"issue":"1-2","key":"10.1002\/14651858.CD006981.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jns.2011.06.016","article-title":"Unilateral parotid electron beam radiotherapy as palliative treatment for sialorrhea in amyotrophic lateral sclerosis","volume":"308","author":"Kasarskis","year":"2011","journal-title":"Journal of the Neurological Sciences"},{"issue":"9","key":"10.1002\/14651858.CD006981.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"e99485","DOI":"10.1371\/journal.pone.0099485","article-title":"Is the pain visual analogue scale linear and responsive to change? An exploration using Rasch analysis","volume":"12","author":"Kersten","year":"2014","journal-title":"PLOS One"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006981.pub3-BIB0051|cit51","first-page":"iv32","article-title":"The management of motor neurone disease","volume":"74","author":"Leigh","year":"2003","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD006981.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S1808-8694(15)31258-1","article-title":"Application of botulinum toxin to reduce the saliva in patients with amyotrophic lateral sclerosis","volume":"71","author":"Manrique","year":"2005","journal-title":"Brazilian Journal of Otorhinolaryngology"},{"key":"10.1002\/14651858.CD006981.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3109\/13682820109177898","article-title":"Drooling in Parkinson's disease: a novel speech and language therapy intervention","volume":"36 Suppl","author":"Marks","year":"2001","journal-title":"International Journal of Language & Communication Disorders"},{"issue":"5","key":"10.1002\/14651858.CD006981.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1212\/WNL.46.5.1442","article-title":"Relationship of the Tufts Quantitative Neuromuscular Exam (TQNE) and the Sickness Impact Profile (SIP) in measuring progression of ALS","volume":"46","author":"McGuire","year":"1996","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD006981.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/PHM.0b013e318164a931","article-title":"Acute deterioration of bulbar function after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis","volume":"87","author":"Meijer","year":"2008","journal-title":"American Journal of Physical Medicine and Rehabilitation"},{"issue":"1","key":"10.1002\/14651858.CD006981.pub3-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.tripleo.2005.08.018","article-title":"Drooling of saliva: a review of the etiology and management options","volume":"101","author":"Meningaud","year":"2006","journal-title":"Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontics"},{"issue":"1","key":"10.1002\/14651858.CD006981.pub3-BIB0057|cit57","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001447.pub3","article-title":"Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND)","author":"Miller","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD006981.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/14660820310011728","article-title":"Percutaneous endoscopic gastrostomy (PEG) in patients with ALS and bulbar dysfunction","volume":"4","author":"Mitsomoto","year":"2003","journal-title":"Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders"},{"issue":"7","key":"10.1002\/14651858.CD006981.pub3-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLOS Medicine"},{"issue":"3","key":"10.1002\/14651858.CD006981.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/00016357.2010.545035","article-title":"Treatment of severe drooling with botulinum toxin in amyotrophic lateral sclerosis and Parkinson's disease: efficacy and possible mechanisms","volume":"69","author":"M\u00f8ller","year":"2011","journal-title":"Acta Odontologica Scandinavica"},{"key":"10.1002\/14651858.CD006981.pub3-BIB0061|cit61","unstructured":"Northeast Amyotrophic Lateral Sclerosis Consortium Become a NEALS Member www.neals.org\/for-als-researchers\/become-a-neals-member"},{"issue":"12","key":"10.1002\/14651858.CD006981.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/j.1468-1331.2007.01983.x","article-title":"Radiotherapy reduces sialorrhea in amyotrophic lateral sclerosis","volume":"14","author":"Neppelberg","year":"2007","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD006981.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0022-510X(96)00104-9","article-title":"The control of oral secretions in bulbar ALS\/MND","volume":"139 Suppl","author":"Newall","year":"1996","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1002\/14651858.CD006981.pub3-BIB0064|cit64","unstructured":"National Institute for Health and Care Excellence Motor Neurone Disease: assessment and management (Guideline No. 42) www.nice.org.uk\/guidance\/ng42\/resources\/motor-neurone-disease-assessment-and-management-pdf-1837449470149"},{"key":"10.1002\/14651858.CD006981.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/0022-510X(96)00087-1","article-title":"The quality of care and symptom control - the effects on the terminal phase of ALS\/MND","volume":"139 Suppl","author":"Oliver","year":"1996","journal-title":"Journal of the Neurological Sciences"},{"issue":"10","key":"10.1002\/14651858.CD006981.pub3-BIB0066|cit66","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s00702-019-02044-6","article-title":"IncobotulinumtoxinA for hypersalivation in patients with amyotrophic lateral sclerosis: an open-label single-centre study","volume":"126","author":"Paracka","year":"2019","journal-title":"Journal of Neural Transmission (Vienna)"},{"issue":"(Pt A)","key":"10.1002\/14651858.CD006981.pub3-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.toxicon.2015.08.014","article-title":"Botulinum toxin A and B in sialorrhea: long-term data and literature overview","volume":"107","author":"Petracca","year":"2015","journal-title":"Toxicon"},{"issue":"4","key":"10.1002\/14651858.CD006981.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1136\/jnnp.70.4.538","article-title":"Treatment of sialorrhoea with ultrasound guided botulinum toxin type A injection in patients with neurological disorders","volume":"70","author":"Porta","year":"2001","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"key":"10.1002\/14651858.CD006981.pub3-BIB0069|cit69","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"18","key":"10.1002\/14651858.CD006981.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.2146\/ajhp100343","article-title":"Manually guided botulinum toxin type A submandibular injections for the treatment of sialorrhea in tube-fed patients with advanced amyotrophic lateral sclerosis","volume":"68","author":"Rodriguez-Murphy","year":"2011","journal-title":"American Journal of Health-System Pharmacy"},{"issue":"9","key":"10.1002\/14651858.CD006981.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1358\/dot.2008.44.9.1258664","article-title":"Dextromethorphan\/quinidine sulfate for pseudobulbar affect","volume":"44","author":"Rosen","year":"2008","journal-title":"Drugs Today"},{"issue":"22","key":"10.1002\/14651858.CD006981.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1056\/NEJM200105313442207","article-title":"Amyotrophic lateral sclerosis","volume":"344","author":"Rowland","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006981.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2273.1985.tb01171.x","article-title":"Reversibility of reduced mucociliary clearance in chronic sinusitis","volume":"10","author":"Sakakura","year":"1985","journal-title":"Clinical Otolaryngology and Allied Sciences"},{"key":"10.1002\/14651858.CD006981.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/21678421.2018.1508477","article-title":"Risk factors for social withdrawal in amyotrophic lateral sclerosis\/motor neurone disease","volume":"19","author":"Schl\u00fcter","year":"2018","journal-title":"Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration"},{"key":"10.1002\/14651858.CD006981.pub3-BIB0075|cit75","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JPT Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3\u00a0(updated February\u00a02022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD006981.pub3-BIB0076|cit76","unstructured":"Sch\u00fcnemann HJ Higgins JPT Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3\u00a0(updated February\u00a02022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"2","key":"10.1002\/14651858.CD006981.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/01.cnd.0000188865.88167.62","article-title":"Parotid gland injections of botulinum toxin A are effective in treating sialorrhea in amyotrophic lateral sclerosis","volume":"7","author":"Scott","year":"2005","journal-title":"Journal of Clinical Neuromuscular Disease"},{"key":"10.1002\/14651858.CD006981.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1136\/bmj.318.7191.1118","article-title":"Motor neurone disease","volume":"318","author":"Shaw","year":"1999","journal-title":"British Medical Journal"},{"issue":"3","key":"10.1002\/14651858.CD006981.pub3-BIB0079|cit79","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1007\/s13311-017-0517-z","article-title":"Erratum to: Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial","volume":"14","author":"Smith","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"8","key":"10.1002\/14651858.CD006981.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1212\/WNL.58.8.1308","article-title":"Results of radiotherapy for drooling in amyotrophic lateral sclerosis","volume":"58","author":"Stalpers","year":"2002","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD006981.pub3-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/00005537-200201000-00014","article-title":"Clinical study of Botulinum-A toxin in the treatment of sialorrhea in children with cerebral palsy","volume":"112","author":"Suskind","year":"2002","journal-title":"Laryngoscope"},{"key":"10.1002\/14651858.CD006981.pub3-BIB0082|cit82","first-page":"225","volume-title":"Handbook of Clinical Neurology","volume":"138","author":"Talbott","year":"2016"},{"issue":"1-2","key":"10.1002\/14651858.CD006981.pub3-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0022-510X(01)00565-2","article-title":"Recurrent jaw dislocation after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis","volume":"190","author":"Tan","year":"2001","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1002\/14651858.CD006981.pub3-BIB0084|cit84","doi-asserted-by":"crossref","unstructured":"Veis S Salivary flow in persons with ALS 11th International Symposium on ALS\/MND; 2000; Aarhus, Denmark (Poster)","DOI":"10.1080\/09699260.2001.11746898"},{"issue":"2","key":"10.1002\/14651858.CD006981.pub3-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/mus.20545","article-title":"Botulinum toxin improves sialorrhea and quality of living in bulbar amyotrophic lateral sclerosis","volume":"34","author":"Verma","year":"2006","journal-title":"Muscle & Nerve"},{"issue":"16","key":"10.1002\/14651858.CD006981.pub3-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/jnnp.s1-4.16.299","article-title":"Some problems in neurology: no. 2 pathological laughing and crying","volume":"4","author":"Wilson","year":"1924","journal-title":"Journal of Neurology and Psychopathology"},{"issue":"3","key":"10.1002\/14651858.CD006981.pub3-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1136\/jnnp.70.3.417","article-title":"Botulinum toxin for the treatment of sialorrhoea in ALS: serious side effects of a transductal approach","volume":"70","author":"Winterholler","year":"2001","journal-title":"Journal of Neurology, Neurosurgery & Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006981.pub3-BIB0088|cit88","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006981","article-title":"Treatment for sialorrhea in people with motor neuron disease or amyotrophic lateral sclerosis","author":"Grundy","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD006981.pub3-BIB0089|cit89","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006981.pub2","article-title":"Treatment for sialorrhea (excessive saliva) in people with motor neuron disease\/amyotrophic lateral sclerosis","author":"Young","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T02:21:32Z","timestamp":1664158892000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006981.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Neuromuscular Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,5,20]]},"references-count":89,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006981.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,20]]}}}